Meotec
Aachen-based medical technology company developing bioabsorbable metal implants via additive manufacturing, enabling patient-specific resorbable devices (magnesium, zinc alloys) that eliminate revision surgery and degrade safely in the body.
- CEO / Founder
- Alexander Kopp
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $781.6K
- Latest Round
- Grant
- Key Investors
- European Union, Abiomed Europe GmbH
Technology & Products
Key Products
Bioabsorbable magnesium/zinc metal implants; resorbable implant system development; surface technology and coating; turnkey process automation for medical devices; contract manufacturing of sophisticated implants (highest risk class)
Technological Advantage
CLAIMED: Controlled in-vivo degradation of metal implants tailored to healing timelines, eliminating hardware removal surgery. VERIFIED: Patent DE102011107577A1 (implant manufacturing method); EU public funding awards (€966K BioStruct — ZnMg alloy AM with algorithm-based lattice; €781K BIOMEND — bioabsorbable metallic endovascular devices; €598K KMU-innovativ-8 — biocompatibility of Mg implants); EIC Pathfinder grant No. 101047008 (BIOMET4D). DEFENSIBLE via patents, trade-secret alloy formulations, and accumulated regulatory dossiers; replication requires years of biocompatibility data and MDR approval cycles.
Differentiation
Value Proposition
Eliminates costly revision surgery by providing bioabsorbable metal implants (Mg, Zn, Fe alloys) that degrade in vivo after healing; combines 10+ years of regulatory expertise (up to highest risk class) with AM-enabled patient-specific lattice structures, offering OEM customers a full-service path from material development to CE-marked contract manufacturing.
How They Differentiate
Meotec targets full-service bioabsorbable metal implant development-to-manufacturing, whereas BIOTRONIK focuses solely on cardiovascular stents with in-house production and does not offer contract manufacturing; unlike Synbone (polymer-dominant, Switzerland), Meotec specializes exclusively in metallic resorbable alloys (Mg, ZnMg) with AM lattice-structure capability and EU MDR regulatory track record for high-risk-class devices — a combination neither competitor offers as a contract service.
Market & Competition
Target Customers
Medical device OEMs and startups requiring development, regulatory approval, and contract manufacturing of bioabsorbable metal implants for orthopedic, cardiovascular, and reconstructive surgery applications
Industry Verticals
Medical; Orthopedics; Cardiovascular; Medical Device Manufacturing
Competitors
BIOTRONIK (Magmaris bioabsorbable magnesium coronary scaffold — same resorbable metal implant segment); Synbone AG (AM-produced synthetic bone models and medical implants — same metal AM medical manufacturing segment)
Growth & Milestones
Growth Metrics
Grew from 2 to ~40 employees; expanded facilities from 160 m² to 700 m² (administration, R&D, development); achieved ISO 13485 quality management certification; spun off Medical Magnesium GmbH for resorbable magnesium implants
Major Milestones
2011: Founded as startup by RWTH Aachen students; 2012: BIOMAGIK trademark registered; 2018: Kermasorb trademark registered; April 2018: Joint venture established (Meotec GmbH & Co.); 1,000 sqm production hall developed; EU KMU-innovativ grant (€598K, Mg implant biocompatibility); EU BIOMEND grant (€781K, bioabsorbable endovascular devices); EU BioStruct grant (€966K, ZnMg alloy AM with lattice structures); EIC Pathfinder grant No. 101047008 (BIOMET4D, coordinated by IMDEA Materials Institute)
Notable Customers
Bioretec Ltd; IMDEA Materials Institute